Infinity Pharmaceuticals Inc. (INFI) Holdings Boosted by Millennium Management LLC

Millennium Management LLC grew its holdings in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) by 105.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,198,854 shares of the biotechnology company’s stock after purchasing an additional 614,806 shares during the quarter. Millennium Management LLC’s holdings in Infinity Pharmaceuticals were worth $2,434,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of INFI. JPMorgan Chase & Co. acquired a new position in Infinity Pharmaceuticals in the third quarter worth $135,000. Alambic Investment Management L.P. acquired a new position in Infinity Pharmaceuticals in the fourth quarter worth $158,000. Wells Fargo & Company MN boosted its stake in Infinity Pharmaceuticals by 654.7% in the fourth quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 91,206 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Infinity Pharmaceuticals by 102.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 150,375 shares of the biotechnology company’s stock worth $305,000 after purchasing an additional 75,980 shares in the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new position in Infinity Pharmaceuticals in the fourth quarter worth $312,000. 49.77% of the stock is currently owned by institutional investors.

Infinity Pharmaceuticals stock opened at $2.26 on Friday. The firm has a market capitalization of $114.32, a price-to-earnings ratio of -2.72 and a beta of 2.49. Infinity Pharmaceuticals Inc. has a 52 week low of $0.93 and a 52 week high of $3.75.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. sell-side analysts expect that Infinity Pharmaceuticals Inc. will post -0.74 EPS for the current year.

In other Infinity Pharmaceuticals news, major shareholder Value Fund L. P. Biotechnology acquired 1,510,000 shares of Infinity Pharmaceuticals stock in a transaction on Tuesday, April 10th. The shares were bought at an average price of $1.97 per share, with a total value of $2,974,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.81% of the stock is currently owned by insiders.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Want to see what other hedge funds are holding INFI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Infinity Pharmaceuticals Inc. (NASDAQ:INFI).

Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply